Eli Lilly and Company

Matthew Robert Reinhard

Karin Briner

Christopher Stanley Galka

Maria Angeles Martinez-Grau

John Gordon Allen

Roger Ryan Rothhaar

Leonard Larry Winneroski, Jr

Michael J Rodriguez

Matthew Joseph Fisher

Timothy Paul Burkholder

Joseph P Burkhart

Yanping Xu

Andrew Caerwyn Williams

Frantz Victor

Shawn Christopher Miller

Jeffrey Thomas Mullaney

Deyi Zhang

Michael Wade Tidwell

Michael Philip Mazanetz

William Harlan Gritton

Brian Eugene Cunningham

John M Schaus

Steven Armen Boyd

Julie M Miyashiro

David Andrew Coates

Yao-Chang Xu

Cynthia Darshini Jesudason

Joseph H Krushinski, Jr

Dennis C Thompson

Ajay Singh

Freddie Craig Stevens

Natalia Pokrovskaia

Michael Philip Cohen

Richard Edmund Rathmell

Richard C Hoying

Manuel Javier Cases-Thomas

Selma Sapmaz

Christopher David Beadle

Junliang Hao

Craig Daniel Wolfangel

John Cunningham O'Toole

Sarah Lynne Hellman

Alicia Marcos Llorente

Arundhati S Deo

Wai-Man Lee

Marta Adeva Bartolome

Karen Briner

Christopher Stephen Siedem

Richard Gerard Conway

John Mehnert Schaus

Joseph Herman Krushinski Jr

Michael John Rodriguez

Joseph Herman Krushinski

The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia. 

[object Object]

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is &#x2014;NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification. 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where:

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N&#x2014;R&#x2033;R* where R6 is &#x2014;(CrC3)alkyl-S&#x2014;(C0-C3)alkyl-R10, &#x2014;(C1-C3)alkyl-NR11R12, &#x2014;(CrC3)alkyl-O&#x2014;R13. and other substituents are as defined in the specification. 

The present invention provides serotonergic benzofurylpiperazines of Formula I:where:

Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists

The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and Rare as described in the specification.

Serotonergic benzofurans

Growing community of inventors

Indianapolis, IN, United States of America

Matthew Robert Reinhard